News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|April 8, 2022

The Burden of ASCVD and Evidence-Based Guidelines

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.

Episodes in this series

EP. 1 The Burden of ASCVD and Evidence-Based Guidelines

EP. 1 The Burden of ASCVD and Evidence-Based Guidelines

EP. 2 A Patient’s Post-MI Journey

EP. 2 A Patient’s Post-MI Journey

EP. 3 Improving the Care Continuum

EP. 3 Improving the Care Continuum

EP. 4 Residual Cardiovascular Risk

EP. 4 Residual Cardiovascular Risk

EP. 5 Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP. 5 Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP. 6 Finding the Optimal Statin Dose

EP. 6 Finding the Optimal Statin Dose

EP. 7 Therapy Beyond Statins in the Inpatient Setting

EP. 7 Therapy Beyond Statins in the Inpatient Setting

EP. 8 Using Adjunct Therapies in LDL Management

EP. 8 Using Adjunct Therapies in LDL Management

EP. 9 Ensuring Continuity of Care for the ASCVD Patient

EP. 9 Ensuring Continuity of Care for the ASCVD Patient

EP. 10 Unmet Needs in Lipid Management

EP. 10 Unmet Needs in Lipid Management

EP. 11 Defining “Optimal Care” for ASCVD Within Health Systems

EP. 11 Defining “Optimal Care” for ASCVD Within Health Systems

EP. 12 What Does a Multidisciplinary Team Look Like?

EP. 12 What Does a Multidisciplinary Team Look Like?

EP. 13 The Future of LDL Management for Patients With High-Risk ASCVD

EP. 13 The Future of LDL Management for Patients With High-Risk ASCVD

EP. 14 Enhancing Patient Care Through Guideline Adherence

EP. 14 Enhancing Patient Care Through Guideline Adherence

EP. 15 Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP. 15 Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP. 16 Appropriate ASCVD Treatment Outside of Closed Health Systems

EP. 16 Appropriate ASCVD Treatment Outside of Closed Health Systems

EP. 17 Utilizing Quality Metrics in ASCVD

EP. 17 Utilizing Quality Metrics in ASCVD

EP. 18 Improving Patient and Provider Engagement

EP. 18 Improving Patient and Provider Engagement

EP. 19 Treatment Disparities in the Management of ASCVD

EP. 19 Treatment Disparities in the Management of ASCVD

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Explore the top dermatology innovations of 2025, from AI-enabled devices to new biologics and emerging treatments for complex skin conditions.

Top 5 Most-Read Dermatology Content of 2025

BySabrina McCrear

December 28th 2025

Highlights From ASH 2025

ICYMI: Highlights From ASH 2025

ByLaura Joszt, MA

December 28th 2025

ICYMI: Highlights From EHA 2025

December 26th 2025

Patient and doctor | Image credit: DragonImages - adobe.stock.com

Sequential BTK and BCL2 Therapy Yields High Initial Real-World Response in CLL

ByKimberly Rath, PharmD

December 26th 2025

The key takeaways from AAD 2025 include expert insights on topical JAK safety, climate-driven skin challenges, tech innovation, and expanding equitable access in dermatology.

ICYMI: Highlights From AAD 2025

BySabrina McCrear

December 25th 2025

Trending on AJMC

Top 5 Most-Read Dermatology Content of 2025

Visibility, Not Lesion Burden, Drives Distress in Alopecia Areata

Top 5 Most-Read CLL Articles of 2025

ICYMI: Highlights From ASH 2025

Top 5 Most-Read "5 Things" Articles of 2025

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.